Prognostic Factors for Surgically Resected Intraductal Papillary Neoplasm of the Bile Duct: A Retrospective Cohort Study.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
16
04
2020
accepted:
24
06
2020
pubmed:
12
7
2020
medline:
15
5
2021
entrez:
12
7
2020
Statut:
ppublish
Résumé
To date, postoperative prognostic factors for intraductal papillary neoplasm of the bile duct (IPNB) have not been well-established. This study aimed to examine the histopathologic features and postoperative prognosis of the two IPNB subclassifications, as well as factors affecting prognosis, based on the authors' experience at a single institution. The study enrolled 83 patients who underwent surgical resection for pathologically diagnosed IPNB at the authors' institution. The clinicopathologic features and postoperative outcomes for these patients were examined. The study also investigated postoperative prognostic factors for IPNB using uni- and multivariate analyses. More than half of the tumors (64%) diagnosed as IPNB were early-stage cancer (UICC Tis or T1). However, none were diagnosed as benign. The multivariate analysis showed that lymph node metastasis (hazard ratio [HR], 5.78; p = 0.002) and bile duct margin status with carcinoma in situ (D-CIS; HR, 5.10; p = 0.002) were independent prognostic factors, whereas MUC6 expression showed only a marginal influence on prediction of prognosis (HR, 0.32; p = 0.07). The tumor recurrence rate and the proportion of locoregional recurrence were significantly greater among the patients with D-CIS than among those with negative bile duct margins, including those patients with low-grade dysplasia. The patients with D-CIS showed a significantly poorer prognosis than those with negative bile duct margins (5-year survival, 38% versus 87%; p = 0.0002). Evaluation of resected IPNBs showed cancer in all cases. Avoiding positive biliary stumps during surgery, including resection of carcinoma in situ, would improve the prognosis for patients with IPNB.
Sections du résumé
BACKGROUND
BACKGROUND
To date, postoperative prognostic factors for intraductal papillary neoplasm of the bile duct (IPNB) have not been well-established. This study aimed to examine the histopathologic features and postoperative prognosis of the two IPNB subclassifications, as well as factors affecting prognosis, based on the authors' experience at a single institution.
METHODS
METHODS
The study enrolled 83 patients who underwent surgical resection for pathologically diagnosed IPNB at the authors' institution. The clinicopathologic features and postoperative outcomes for these patients were examined. The study also investigated postoperative prognostic factors for IPNB using uni- and multivariate analyses.
RESULTS
RESULTS
More than half of the tumors (64%) diagnosed as IPNB were early-stage cancer (UICC Tis or T1). However, none were diagnosed as benign. The multivariate analysis showed that lymph node metastasis (hazard ratio [HR], 5.78; p = 0.002) and bile duct margin status with carcinoma in situ (D-CIS; HR, 5.10; p = 0.002) were independent prognostic factors, whereas MUC6 expression showed only a marginal influence on prediction of prognosis (HR, 0.32; p = 0.07). The tumor recurrence rate and the proportion of locoregional recurrence were significantly greater among the patients with D-CIS than among those with negative bile duct margins, including those patients with low-grade dysplasia. The patients with D-CIS showed a significantly poorer prognosis than those with negative bile duct margins (5-year survival, 38% versus 87%; p = 0.0002).
CONCLUSIONS
CONCLUSIONS
Evaluation of resected IPNBs showed cancer in all cases. Avoiding positive biliary stumps during surgery, including resection of carcinoma in situ, would improve the prognosis for patients with IPNB.
Identifiants
pubmed: 32651697
doi: 10.1245/s10434-020-08835-6
pii: 10.1245/s10434-020-08835-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
826-834Références
Lokuhetty D, White VA, Watanabe R, Cree IA, World Health Organization, International Agency for Research on Cancer. Digestive system tumours. 5th ed. International Agency for Research on Cancer, Lyon, 2019.
Gordon-Weeks AN, Jones K, Harriss E, Smith A, Silva M. Systematic review and meta-analysis of current experience in treating IPNB: clinical and pathological correlates. Ann Surg. 2016;263:656–63.
pubmed: 26501712
Kloek JJ, van der Gaag NA, Erdogan D, et al. A comparative study of intraductal papillary neoplasia of the biliary tract and pancreas. Hum Pathol. 2011;42:824–32.
pubmed: 21292296
Rocha FG, Lee H, Katabi N, et al. Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas? Hepatology. 2012;56:1352–60.
pubmed: 22504729
Jung G, Park KM, Lee SS, Yu E, Hong SM, Kim J. Long-term clinical outcome of the surgically resected intraductal papillary neoplasm of the bile duct. J Hepatol. 2012;57:787–93.
pubmed: 22634127
Kang MJ, Jang JY, Lee KB, Han IW, Kim SW. Impact of macroscopic morphology, multifocality, and mucin secretion on survival outcome of intraductal papillary neoplasm of the bile duct. J Gastrointest Surg. 2013;17:931–8.
pubmed: 23371308
Bosman FT, World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of the digestive system. 4th ed. International Agency for Research on Cancer, Lyon, 2010.
Nakanuma Y, Jang KT, Fukushima N, et al. A statement by the Japan-Korea expert pathologists for future clinicopathological and molecular analyses toward consensus building of intraductal papillary neoplasm of the bile duct through several opinions at the present stage. J Hepatobiliary Pancreat Sci. 2018;25:181–7.
pubmed: 29272078
Yang CY, Huang WJ, Tsai JH, et al. Targeted next-generation sequencing identifies distinct clinicopathologic and molecular entities of intraductal papillary neoplasms of the bile duct. Mod Pathol. 2019;32:1637–45.
pubmed: 31231124
Sobin LH, Gospodarowicz MK, Wittekind C, International Union Against Cancer. TNM classification of malignant tumours. 7th ed. Chichester, Hoboken: Ebrary Inc, Wiley-Blackwell, 2009.
Albores-Saavedra J, Henson DE, Sobin LH. WHO histological typing of tumors of the gallbladder and extrahepatic bile ducts. 2nd ed. Springer, Berlin, 1991.
Albores-Saavedra J, Henson DE. Tumors of the gallbladder, extrahepatic bile ducts, and ampulla of vater. Published by the Armed Forces Institute of Pathology under the auspices of Universities Assocaited for Research and Education in Pathology, Washington, D.C., 2000.
Zen Y, Fujii T, Itatsu K, et al. Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas. Hepatology. 2006;44:1333–43.
pubmed: 17058219
Chen TC, Nakanuma Y, Zen Y, et al. Intraductal papillary neoplasia of the liver associated with hepatolithiasis. Hepatology. 2001;34(4 Pt 1):651–8.
pubmed: 11584359
Zen Y, Fujii T, Itatsu K, et al. Biliary cystic tumors with bile duct communication: a cystic variant of intraductal papillary neoplasm of the bile duct. Mod Pathol. 2006;19:1243–54.
pubmed: 16741522
Zen Y, Sasaki M, Fujii T, et al. Different expression patterns of mucin core proteins and cytokeratins during intrahepatic cholangiocarcinogenesis from biliary intraepithelial neoplasia and intraductal papillary neoplasm of the bile duct: an immunohistochemical study of 110 cases of hepatolithiasis. J Hepatol. 2006;44:350–8.
pubmed: 16360234
Yonezawa S, Nakamura A, Horinouchi M, Sato E. The expression of several types of mucin is related to the biological behavior of pancreatic neoplasms. J Hepatobiliary Pancreat Surg. 2002;9:328–41.
pubmed: 12353144
Pinto-de-Sousa J, David L, Reis CA, Gomes R, Silva L, Pimenta A. Mucins MUC1, MUC2, MUC5AC, and MUC6 expression in the evaluation of differentiation and clinico-biological behaviour of gastric carcinoma. Virchows Arch. 2002;440:304–10.
pubmed: 11889602
Nakanuma Y, Sato Y, Ojima H, et al. Clinicopathological characterization of so-called “cholangiocarcinoma with intraductal papillary growth” with respect to “intraductal papillary neoplasm of bile duct (IPNB).” Int J Clin Exp Pathol. 2014;7:3112–22.
pubmed: 25031730
pmcid: 4097227
Onoe S, Shimoyama Y, Ebata T, et al. Prognostic delineation of papillary cholangiocarcinoma based on the invasive proportion: a single-institution study with 184 patients. Surgery. 2014;155:280–91.
pubmed: 24287144
Tsukahara T, Ebata T, Shimoyama Y, et al. Residual carcinoma in situ at the ductal stump has a negative survival effect: an analysis of early-stage cholangiocarcinomas. Ann Surg. 2017;266:126–32.
pubmed: 27501166
Higuchi R, Yazawa T, Uemura S, Izumo W, Furukawa T, Yamamoto M. High-grade dysplasia/carcinoma in situ of the bile duct margin in patients with surgically resected node-negative perihilar cholangiocarcinoma is associated with poor survival: a retrospective study. J Hepatobiliary Pancreat Sci. 2017;24:456–65.
pubmed: 28547855
Wakai T, Shirai Y, Moroda T, Yokoyama N, Hatakeyama K. Impact of ductal resection margin status on long-term survival in patients undergoing resection for extrahepatic cholangiocarcinoma. Cancer. 2005;103:1210–6.
pubmed: 15685618
Higuchi R, Ota T, Araida T, Kobayashi M, Furukawa T, Yamamoto M. Prognostic relevance of ductal margins in operative resection of bile duct cancer. Surgery. 2010;148:7–14.
pubmed: 20116818
Kim WJ, Hwang S, Lee YJ, et al. Clinicopathological features and long-term outcomes of intraductal papillary neoplasms of the intrahepatic bile duct. J Gastrointest Surg. 2016;20:1368–75.
pubmed: 26873016
Kubota K, Nakanuma Y, Kondo F, et al. Clinicopathological features and prognosis of mucin-producing bile duct tumor and mucinous cystic tumor of the liver: a multi-institutional study by the Japan Biliary Association. J Hepatobiliary Pancreat Sci. 2014;21:176–85.
pubmed: 23908126
Bartman AE, Buisine MP, Aubert JP, et al. The MUC6 secretory mucin gene is expressed in a wide variety of epithelial tissues. J Pathol. 1998;186:398–405.
pubmed: 10209489
Furukawa T. Subtyping of IPMN. Methods Mol Biol. 2019;1882:1–8.
Thuwajit P, Chawengrattanachot W, Thuwajit C, Sripa B, Paupairoj A, Chau-In S. Enhanced expression of mucin 6 glycoprotein in cholangiocarcinoma tissue from patients in Thailand as a prognostic marker for survival. J Gastroenterol Hepatol. 2008;23:771–8.
pubmed: 18410610
Aishima S, Kuroda Y, Nishihara Y, et al. Gastric mucin phenotype defines tumour progression and prognosis of intrahepatic cholangiocarcinoma: gastric foveolar type is associated with aggressive tumour behaviour. Histopathology. 2006;49:35–44.
pubmed: 16842244
Harada F, Matsuyama R, Mori R, et al. Outcomes of surgery for 2010 WHO classification-based intraductal papillary neoplasm of the bile duct: case-control study of a single Japanese institution’s experience with special attention to mucin expression patterns. Eur J Surg Oncol. 2019;45:761–8.
pubmed: 30389302